Pilots

JA PCM is structured around seven pilot interventions designed to explore and scale up personalised approaches to cancer prevention, diagnosis, treatment, and follow-up across Europe. These pilots are embedded in the three technical arms of the project and supported by transversal work packages on data, ethics, and quality assurance.

Each pilot tests a real-world application of personalised cancer medicine, helping countries address key challenges around implementation, data use, and access.

Explore the pilots:

Arm I – Personalised prevention and early detection

• Pathway, access, and implementation of risk-informed cancer prevention across Europe (PARI)
  Developing and testing care pathways that adapt cancer prevention strategies to individual risk profiles
• Implementation readiness for polygenic risk scores in screening (PRS)
  Exploring how genetic information can help better estimate cancer risk and inform prevention.

Arm II – Personalised medicine

• Supranational molecular tumor board for complex cases/countries with no MTB (MTB)
  Strengthening the use of molecular data to support clinical decision-making in multidisciplinary tumour board meetings.
• Continuous data collection via a federated sharing platform
  Developing ways to securely collect and analyse real-world cancer data from multiple countries, in order to build larger patient cohorts and generate evidence that can inform decisions on cancer treatments and improve patient outcomes.
  The pilot contains two use cases: 1) Expanding Treatment Space; and 2) Managed Entry Agreements 

Arm III – Personalised follow-up and tertiary prevention

• Digital tools for survivorship care delivery
  Deploying a personalized implementation package to advance digital survivorship care delivery (needs assessment, care coordination, remote monitoring, self-management support and supportive care delivery) across diverse centres.

Transversal pilots

• Personalised management of cancer predisposition across the patient journey
  Integrating information on genetic predisposition into different stages of the patient journey, from screening to follow-up.
• Implementation of liquid biopsy across the patient journey
  Applying liquid biopsy techniques in different clinical contexts including screening, treatment monitoring, and recurrence surveillance.